Delaware Court Allows Obviousness Challenge in Astellas Pharma Bladder Drug Patent Dispute

In a noteworthy development in the pharmaceutical patent landscape, a Delaware federal judge has permitted two manufacturers of generic bladder medication to argue that patents owned by Astellas Pharma Inc. are invalid due to obviousness. This decision lifts a previous stipulation that had restricted these generic drug manufacturers from making such a claim. The judge’s ruling aligns with the allowance of similar arguments to be presented by other generic-drug producers embroiled in the ongoing consolidated litigation. This case will further unfold at a bench trial expected to take place later this year. For more details, please refer to the full article.